Loading clinical trials...
Loading clinical trials...
An International, Randomized, Double-Blinded, Phase 3 Efficacy Study of XL184 Versus Placebo in Subjects With Unresectable, Locally Advanced, or Metastatic Medullary Thyroid Cancer
Conditions
Interventions
XL184
Placebo
Locations
113
United States
University of Alabama at Birmingham, Comprehensive Cancer Center
Birmingham, Alabama, United States
TGEN Clinical Research Service at Scottsdale Healthcare
Scottsdale, Arizona, United States
University of Arkansas for Medical Sciences
Little Rock, Arkansas, United States
Burbank, California, United States
UCLA
Los Angeles, California, United States
Stanford Cancer Center
Stanford, California, United States
Start Date
June 1, 2008
Primary Completion Date
October 1, 2011
Completion Date
September 1, 2020
Last Updated
April 20, 2021
NCT06316895
NCT07092514
NCT07436455
NCT06558981
NCT06524167
NCT01660984
Lead Sponsor
Exelixis
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions